Participated · Series A · Aug 2026

Remepy develops Hybrid Drugs that integrate prescription medicines with personalized, AI-driven therapeutic apps to combine pharmacology with adaptive physical, cognitive, and behavioral interventions. The company partners with pharmaceutical firms to co-develop these drug–software combination products and recently announced a strategic collaboration with Merck KGaA. Remepy’s lead program, Hybridopa for Parkinson’s disease, produced encouraging Phase IIa results supported by peer‑reviewed publications and is being prepared for a global Phase III trial expected to begin in Q4 2026. The Series A financing and existing investor base have brought total capital raised to $62 million, providing funds to expand the company’s pipeline, platform, and pharmaceutical partnerships. Remepy positions its approach within emerging FDA frameworks for drug‑software combination products and aims to create new IP and lifecycle-management opportunities for partner drugs.

Led · Series B · Aug 2026

QuantHealth offers an AI-driven clinical trial simulation platform that enables life sciences companies to evaluate, optimize, and de-risk clinical and commercial decisions before enrolling patients or committing capital. The company serves pharmaceutical and biotechnology organizations and is led by CEO Orr Inbar. QuantHealth is based in Tel Aviv, Israel. Following its Series B, the company plans to scale enterprise-wide impact, accelerate adoption of simulation-first clinical development, advance R&D capabilities, grow its workforce, and expand its product portfolio. The article does not disclose revenues, user counts, or prior funding rounds.

Participated · Series C · Aug 2026

Zenity builds a platform that gives security teams visibility, enforcement and response capabilities specifically for AI agents, allowing deterministic blocking, modification or allowance of agent actions by understanding intent. The company serves a majority of customers in the Fortune 500, Global 2000 and highly regulated industries such as financial services, healthcare, pharmaceuticals, energy and manufacturing. Zenity operates Zenity Labs, whose research has uncovered industry-defining vulnerabilities—examples include AgentFlayer and other disclosed flaws in agentic frameworks and integrations. The company has more than 230 employees, with R&D centered in Tel Aviv and go-to-market and operations led from New York. Financially, Zenity reported tripling revenue in each of the past two years and said it is on track to triple revenue again this year. Going forward, Zenity plans to use its new funding to accelerate platform innovation, expand Zenity Labs and grow its global footprint, particularly across Europe and Asia Pacific.

Participated · Equity · Jul 2026

TytoCare develops a clinician-grade handheld remote examination platform paired with FDA-cleared AI-powered software-as-a-medical-device algorithms to enable comprehensive remote physical exams. The company serves health systems, payers, and employer health programs and is positioning its platform for cardiopulmonary screening, oncology supportive care, and chronic disease management including CHF and COPD. TytoCare announced leadership appointments of Adam Pellegrini as CEO and Greg Orr as COO concurrent with its $25M+ growth round led by Insight Partners. The company intends to use the new capital to expand its AI algorithm pipeline, deepen integrations with health systems and payers, and accelerate go-to-market efforts. TytoCare is headquartered in New York and Netanya, Israel, and emphasizes FDA-cleared diagnostic fidelity as a competitive differentiator.

Led · Series B · Mar 2026

Qodo builds AI agents that review, test and govern code by reasoning about how changes affect entire systems and factoring in organizational standards, historical context, and risk tolerance. The company emphasizes system-level verification rather than just focusing on diffs, positioning its technology to address trust and reliability gaps in AI-generated code. Qodo launched Qodo 2.0, a multi-agent code review system, and introduced tools that learn each organization’s definition of code quality. It ranked No. 1 on Martian’s Code Review Bench with a 64.3% score, outperforming competitors on tricky logic bugs and cross-file issues. The startup was founded in 2022 by Itamar Friedman and is headquartered in New York. Qodo counts customers such as NVIDIA, Walmart, Red Hat, Intuit, Texas Instruments, Monday.com, and JFrog.